Literature DB >> 16174071

Cirrhotic rats with bacterial translocation have higher incidence and severity of hepatopulmonary syndrome.

Benjamin Sztrymf1, Jean-Marie Libert, Christine Mougeot, Didier Lebrec, Michel Mazmanian, Marc Humbert, Philippe Herve.   

Abstract

BACKGROUND: Bacterial translocation, that is, extra-intestinal dissemination of gut bacteria, occurs in approximately 50% of humans and rats with cirrhosis and plays a significant role in enhanced tumor necrosis factor-alpha (TNF-alpha) production. The authors' previous studies have indicated that prevention of bacterial translocation with norfloxacine or inhibition of TNF-alpha with pentoxifylline treatment decreased both the incidence and severity of hepatopulmonary syndrome by attenuating the induction of pulmonary intravascular macrophages in cirrhotic rats. In the present study the hypothesis was tested that the cirrhotic rats with bacterial translocation had higher TNF-alpha production, higher level of sequestration of macrophages in pulmonary vessels, and increased incidence and severity of hepatopulmonary syndrome.
METHODS: Rats were studied 5 weeks after common bile duct ligation or sham operation. Bacterial translocation was defined by positive mesenteric lymph node cultures. Hepatopulmonary syndrome was assessed by measurements of alveoloarterial oxygen difference (AaPO(2)) and intrapulmonary shunt. The TNF-alpha concentration in plasma was measured by ELISA. Pulmonary intravascular macrophage sequestration was assessed by lung morphometric analysis.
RESULTS: Bacterial translocation occurred in 48% of cirrhotic rats. Plasma concentrations of TNF-alpha and the percentage of vessels with pulmonary intravascular macrophages were higher in the cirrhotic rats with bacterial translocation. Rats with bacterial translocation also had a higher incidence (9% vs 63%, P < 0.01) and severity of hepatopulmonary syndrome, as indicated by higher levels of both AaPO(2) and intrapulmonary shunt.
CONCLUSIONS: These results suggest that bacterial translocation may play a role in the pathogenesis of hepatopulmonary syndrome by inducing pulmonary intravascular macrophages through TNF-alpha upregulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16174071     DOI: 10.1111/j.1440-1746.2005.03914.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  17 in total

1.  The association of lipopolysaccharide and inflammatory factors with hepatopulmonary syndrome and their changes after orthotopic liver transplantation.

Authors:  Huimin Yi; Yuling An; Haijin Lv; Xuxia Wei; Xiaomeng Yi; Genshu Wang; Yang Yang; Guihua Chen; Shuhong Yi
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 2.  Hepatopulmonary syndrome: What we know and what we would like to know.

Authors:  Israel Grilo-Bensusan; Juan Manuel Pascasio-Acevedo
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

3.  Mechanisms by which chronic ethanol feeding limits the ability of dendritic cells to stimulate T-cell proliferation.

Authors:  Ji Fan; Michelle R Edsen-Moore; Lucas E Turner; Robert T Cook; Kevin L Legge; Thomas J Waldschmidt; Annette J Schlueter
Journal:  Alcohol Clin Exp Res       Date:  2010-10-06       Impact factor: 3.455

Review 4.  Hepatopulmonary Syndrome.

Authors:  Yong Lv; Daiming Fan
Journal:  Dig Dis Sci       Date:  2015-03-03       Impact factor: 3.199

Review 5.  Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.

Authors:  Sarah Raevens; Michael B Fallon
Journal:  Hepatology       Date:  2018-11       Impact factor: 17.425

6.  Hepatopulmonary syndrome: the role of intra-abdominal hypertension and a novel mouse model.

Authors:  Zhaojie Zhang; Xiaolong Qi; Zhiwei Li; Lijun Xu; Fei Wang; Shenglan Wang; Yizhong Chang; Wanrong Ma; Mingxin Xu; Changqing Yang
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

7.  The interstitial lymphatic peritoneal mesothelium axis in portal hypertensive ascites: when in danger, go back to the sea.

Authors:  M A Aller; I Prieto; S Argudo; F de Vicente; L Santamaría; M P de Miguel; J L Arias; J Arias
Journal:  Int J Inflam       Date:  2010-10-05

Review 8.  Pulmonary complications of hepatic diseases.

Authors:  Salim R Surani; Yamely Mendez; Humayun Anjum; Joseph Varon
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

Review 9.  Clinical and pathophysiological consequences of alterations in the microbiome in cirrhosis.

Authors:  Jane Macnaughtan; Rajiv Jalan
Journal:  Am J Gastroenterol       Date:  2015-09-29       Impact factor: 10.864

10.  Experimental obstructive cholestasis: the wound-like inflammatory liver response.

Authors:  María-Angeles Aller; Jorge-Luis Arias; Jose García-Domínguez; Jose-Ignacio Arias; Manuel Durán; Jaime Arias
Journal:  Fibrogenesis Tissue Repair       Date:  2008-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.